Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

The Medicines Co. to buy Ionsys developer Incline Therapeutics for $185mm

Executive Summary

On the same day it gained rights to BMS’s active hemostat Recothrom, critical care-focused The Medicines Co. (TMC) is adding yet another product to its portfolio, through the acquisition of privately held Incline Therapeutics Inc. for $185mm in cash up front plus up to $205mm in earn-outs tied to the following: signing a Japanese licensing agreement for Incline’s acute postoperative pain candidate Ionsys; and achieving regulatory approvals and sales milestones.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Cash

Related Companies